Aromatase inhibitors: a useful additional therapeutic option for slowing down advanced bone age in boys with growth hormone deficiency
ConclusionsWhen used in addition to rhGH therapy in boys with GHD and advanced BA, AIs were observed to slow down the tempo of BA maturation after 1 year, compared to those who received rhGH treatment alone. AI therapy was found to be safe during the 1-year observation period and thus could be considered for preserving growth potential in these patients. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - December 1, 2023 Category: Endocrinology Source Type: research
EE81 Cost-Effectiveness of CDK 4/6I for the Treatment of Postmenopausal Patients With Advanced Breast Cancer HR-Positive, HER2-Negative From the Point of View of the Payer of the Public Health System in Panama
The aim of this study is to estimate the cost-effectiveness of ribociclib + letrozole, Abemaciclib + letrozole or ANAS (Anastrozole) versus palbociclib + letrozole in the treatment of HR-positive, HER2-negative advanced breast cancer patients in the first line of treatment from the perspective of the National Cancer Institute of Panama (ION). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: O. Castillo-Fernandez, G. Sinta Source Type: research
A Systematic Review of Novel Therapies of Pulmonary Arterial Hypertension
ConclusionMetformin and sotatercept appear as promising therapeutic drugs for PAH.Clinical Trials RegistrationThis work was registered in PROSPERO (CDR42022340658). (Source: American Journal of Cardiovascular Drugs)
Source: American Journal of Cardiovascular Drugs - November 9, 2023 Category: Cardiology Source Type: research
Drug that cuts breast cancer risk set for wider use in UK
An oral medicine called anastrozole has been approved by the UK ' s drug regulatory agency for reducing the risk of breast cancer in post-menopausal women at moderate-to-high risk of the condition (Source: New Scientist - Health)
Source: New Scientist - Health - November 7, 2023 Category: Consumer Health News Source Type: research
Risk of ocular adverse events with aromatase inhibitors
CONCLUSION: Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.PMID:37931898 | DOI:10.1016/j.jcjo.2023.10.013 (Source: Cancer Control)
Source: Cancer Control - November 6, 2023 Category: Cancer & Oncology Authors: Zhao Xun Feng Aswen Sriranganathan Cody Lo Victoria Liu David Maberley Mahyar Etminan Source Type: research
Risk of ocular adverse events with aromatase inhibitors
CONCLUSION: Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.PMID:37931898 | DOI:10.1016/j.jcjo.2023.10.013 (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - November 6, 2023 Category: Opthalmology Authors: Zhao Xun Feng Aswen Sriranganathan Cody Lo Victoria Liu David Maberley Mahyar Etminan Source Type: research
Risk of ocular adverse events with aromatase inhibitors
CONCLUSION: Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.PMID:37931898 | DOI:10.1016/j.jcjo.2023.10.013 (Source: Canadian Journal of Ophthalmology)
Source: Canadian Journal of Ophthalmology - November 6, 2023 Category: Opthalmology Authors: Zhao Xun Feng Aswen Sriranganathan Cody Lo Victoria Liu David Maberley Mahyar Etminan Source Type: research
Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer
CONCLUSIONS: Elacestrant gained FDA approval in January 2023 and can be considered in patients with HR+ HER2- advanced breast cancer and ESR1 mutations who have progressed despite therapy with either CDK 4/6i plus aromatase inhibitors (AI) or fulvestrant or chemotherapy.PMID:37888769 | DOI:10.1177/10600280231206131 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - October 27, 2023 Category: Drugs & Pharmacology Authors: Elizabeth Hageman Mia E Lussier Source Type: research
Non-aromatizable androgens modulate the lipopolysaccharide induced expression of the P2X7 receptor in human adipocytes
Discussion: The purinergic system is involved in the inflammatory response of adipocytes, and androgens may modulate its activity. In particular DHT, a non-aromatizable androgen, amplifies the LPS-induced P2X7R gene expression in human adipocytes thus showing a gender regulated response of the expression of this purinergic receptor strongly involved in the inflammatory response in adipose tissue. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - October 23, 2023 Category: Drugs & Pharmacology Source Type: research
Neurocognitive impairment in females with breast cancer treated with endocrine therapy and CDK4/6 inhibitors: a pharmacovigilance study using the World Health Organization ’s database
Conclusion: These findings suggest that in females treated for breast cancer, all ETs may be associated with NCI. However, amongst iCDK4/6s, NCI may be specific to palbociclib. NCI most frequently involved learning and memory as well as language. Neurocognitive impact of treatments requires better consideration and management. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - October 20, 2023 Category: Drugs & Pharmacology Source Type: research
Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
CONCLUSIONS: Apatinib plus exemestane exhibited objective efficacy in patients with ER+/HER2- MBC who have failed multiple lines of treatment. The AEs of apatinib required close monitoring and most of patients were well tolerated.PMID:37831547 | DOI:10.1080/15384047.2023.2265055 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 13, 2023 Category: Cancer & Oncology Authors: Aihua Tan Li Nong Hongxue Wang Yuxian Jia Wuning Zhong Fanghui Qin Han Wang Jing Tang Yan Liu Yongkui Lu Source Type: research
Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
CONCLUSIONS: Apatinib plus exemestane exhibited objective efficacy in patients with ER+/HER2- MBC who have failed multiple lines of treatment. The AEs of apatinib required close monitoring and most of patients were well tolerated.PMID:37831547 | DOI:10.1080/15384047.2023.2265055 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 13, 2023 Category: Cancer & Oncology Authors: Aihua Tan Li Nong Hongxue Wang Yuxian Jia Wuning Zhong Fanghui Qin Han Wang Jing Tang Yan Liu Yongkui Lu Source Type: research
Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
CONCLUSIONS: Apatinib plus exemestane exhibited objective efficacy in patients with ER+/HER2- MBC who have failed multiple lines of treatment. The AEs of apatinib required close monitoring and most of patients were well tolerated.PMID:37831547 | DOI:10.1080/15384047.2023.2265055 (Source: Cancer Biology and Therapy)
Source: Cancer Biology and Therapy - October 13, 2023 Category: Cancer & Oncology Authors: Aihua Tan Li Nong Hongxue Wang Yuxian Jia Wuning Zhong Fanghui Qin Han Wang Jing Tang Yan Liu Yongkui Lu Source Type: research
27-Hydroxycholesterol impairs learning and memory ability via decreasing brain glucose uptake mediated by the gut microbiota
This study aimed to investigate the link between 27-OHC, the gut microbiota, and brain glucose uptake in AD. Here, 6-month-old male C57BL/6 J mice were treated with sterile water or antibiotic cocktails, with or without 27-OHC and/or 27-OHC synthetic enzyme CYP27A1 inhibitor anastrozole (ANS). The gut microbiota, brain glucose uptake levels, and memory ability were measured. We observed that 27-OHC altered microbiota composition, damaged brain tissue structures, decreased the 2-deoxy-2-[18 F] fluorodeoxyglucose (18F-FDG) uptake value, downregulated the gene expression of glucose transporter type 4 (GLUT4), reduced the colo...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 8, 2023 Category: Drugs & Pharmacology Authors: Ling Hao Lijing Wang Mengwei Ju Wenjing Feng Zhiting Guo Xuejing Sun Rong Xiao Source Type: research
